Guideline Summary NGC-8807

**Guideline Title**

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis.

**Bibliographic Source(s)**


**Guideline Status**

This is the current release of the guideline.


**Scope**

**Disease/Condition(s)**

- Postmenopausal osteoporosis

**Guideline Category**

- Diagnosis
- Evaluation
- Management
- Prevention
- Risk Assessment
- Treatment

**Clinical Specialty**

- Endocrinology
- Family Practice
- Geriatrics
- Internal Medicine

**Intended Users**

- Health Care Providers
- Health Plans
- Managed Care Organizations
- Patients
- Physicians
- Public Health Departments

**Guideline Objective(s)**

- To reduce the risk of osteoporosis-related fractures and thereby improve the quality of life for people with
To reduce the risk of osteoporosis (related fractures and therapy) improve the quality of life for people with osteoporosis

- To provide evidence-based information about the diagnosis, evaluation, and treatment of postmenopausal osteoporosis

**Target Population**

Postmenopausal women

**Interventions and Practices Considered**

**Prevention/Risk Assessment**

1. Assessment of postmenopausal osteoporosis risk factors using the Fracture Risk Assessment (FRAX) tool
2. Adequate calcium and vitamin D intake, through supplements as needed
3. Limiting alcohol and caffeine intake
4. Avoidance or cessation of smoking
5. Maintaining an active lifestyle

**Diagnosis/Evaluation**

1. Bone density measurement using dual-energy x-ray absorptiometry (DXA)
2. Evaluation for secondary osteoporosis and prevalent vertebral fractures

**Treatment/Management**

1. Adequate protein intake
2. Use of proper body mechanics
3. Use of hip protectors and protective measures to reduce risk of falling
4. Referral for physical and occupational therapy
5. Pharmacologic agents
   - First-line therapy: alendronate, risedronate, zoledronic acid, denosumab
   - Second-line therapy: ibandronate
   - Second- and third-line therapy: raloxifene
   - Last-line therapy: calcitonin
   - Bisphosphonate failure or very high fracture risk: teriparatide
6. Monitoring of treatment with change in bone density
7. Treatment holidays
8. Referral to a clinical endocrinologist

*Note:* Combination pharmacologic therapy was considered but not recommended; surgical repair of spinal fractures was considered but data were insufficient for a recommendation.

**Major Outcomes Considered**

- Mortality due to postmenopausal osteoporosis, particularly hip fracture
- Symptoms of fractures, skeletal deformity, and physical function
- Rates of bone loss
- Risk and incidence of fractures, falls, and injury
- Changes in bone mineral density measurements or bone turnover markers
- Side effects and cost effectiveness of treatment

**Methodology**

**Methods Used to Collect/Select the Evidence**

Searches of Electronic Databases

**Description of Methods Used to Collect/Select the Evidence**

PubMed was searched and updates included papers published since the last guideline in 2003. Search terms used were: osteoporosis treatment and evaluation. Reviews and high level references were included. Opinion papers were not included.

**Number of Source Documents**

Not stated

**Methods Used to Assess the Quality and Strength of the Evidence**
Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)

Rating Scheme for the Strength of the Evidence

2010 American Association of Clinical Endocrinologists Criteria for Rating of Published Evidence*

<table>
<thead>
<tr>
<th>Numerical Descriptor (evidence level)</th>
<th>Semantic Descriptor (reference methods)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Meta-analysis of randomized controlled trials</td>
</tr>
<tr>
<td>1</td>
<td>Randomized controlled trial</td>
</tr>
<tr>
<td>2</td>
<td>Meta-analysis of nonrandomized prospective or case-controlled trials</td>
</tr>
<tr>
<td>2</td>
<td>Nonrandomized controlled trial</td>
</tr>
<tr>
<td>2</td>
<td>Prospective cohort study</td>
</tr>
<tr>
<td>2</td>
<td>Retrospective case-control study</td>
</tr>
<tr>
<td>3</td>
<td>Cross-sectional study</td>
</tr>
<tr>
<td>3</td>
<td>Surveillance study (registries, surveys, epidemiologic study)</td>
</tr>
<tr>
<td>3</td>
<td>Consecutive case series</td>
</tr>
<tr>
<td>3</td>
<td>Single case reports</td>
</tr>
<tr>
<td>4</td>
<td>No evidence (theory, opinion, consensus, or review)</td>
</tr>
</tbody>
</table>

*1 = strong evidence; 2 = intermediate evidence; 3 = weak evidence; 4 = no evidence.


Methods Used to Analyze the Evidence

Review of Published Meta-Analyses

Systematic Review

Description of the Methods Used to Analyze the Evidence

Expert opinion was used to evaluate the available literature and to grade references relative to evidence level (see the "Rating Scheme for the Strength of the Evidence" field), based on the ratings of 1 through 4 from the 2010 American Association of Clinical Endocrinologists (AACE) protocol for standardized production of clinical practice guidelines.

Methods Used to Formulate the Recommendations

Expert Consensus

Description of Methods Used to Formulate the Recommendations

The guidelines used the best evidence, taking into consideration the economic impact of the disease and the need for efficient and effective evaluation and treatment of postmenopausal women with osteoporosis.

Recommendations were graded A through D, in accordance with methods established by the American Association of Clinical Endocrinologists (AACE) in 2004 (see the "Rating Scheme for the Strength of the Recommendations" field). Information pertaining to cost-effectiveness was included when available.

Rating Scheme for the Strength of the Recommendations

American Association of Clinical Endocrinologists Criteria for Grading of Recommendations

<table>
<thead>
<tr>
<th>Recommendation Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Homogeneous evidence from multiple well-designed randomized controlled trials with sufficient statistical power</td>
</tr>
<tr>
<td></td>
<td>Homogeneous evidence from multiple well-designed cohort controlled trials with sufficient statistical power</td>
</tr>
<tr>
<td></td>
<td>≥1 conclusive level 1 publications demonstrating benefit &gt;&gt; risk</td>
</tr>
<tr>
<td>B</td>
<td>Evidence from at least 1 large well-designed clinical trial, cohort or case-controlled analytic study, or meta-analysis</td>
</tr>
<tr>
<td></td>
<td>No conclusive level 1 publication; ≥1 conclusive level 2 publications demonstrating benefit &gt;&gt; risk</td>
</tr>
<tr>
<td>C</td>
<td>Evidence based on clinical experience, descriptive studies, or expert consensus opinion</td>
</tr>
<tr>
<td></td>
<td>No conclusive level 1 or 2 publications; ≥1 conclusive level 3 publications demonstrating benefit &gt;&gt; risk</td>
</tr>
<tr>
<td></td>
<td>No conclusive risk at all and no conclusive benefit demonstrated by evidence</td>
</tr>
<tr>
<td>D</td>
<td>Not rated</td>
</tr>
<tr>
<td></td>
<td>No conclusive level 1, 2, or 3 publication demonstrating benefit &gt;&gt; risk</td>
</tr>
<tr>
<td></td>
<td>Conclusive level 1, 2, or 3 publication demonstrating risk &gt;&gt; benefit</td>
</tr>
</tbody>
</table>
Cost Analysis

- The cost-effectiveness of bone mineral density (BMD) testing and its benefits to society are controversial. Clinicians, politicians, patients, industry, and third-party payers all have different perspectives on the indications for and timing of BMD measurements. The current recommendations are intended to outline reasonable use of this technology within the context of the endocrine specialty practice. Because universal BMD testing is not cost-effective, the American Association of Clinical Endocrinologists (AACE) recommendations for screening include women 65 years of age or older and younger postmenopausal women at increased risk based on fracture risk analysis.

- AACE has endorsed the 2008 National Osteoporosis Foundation Clinician’s Guide to Prevention and Treatment of Osteoporosis. The Guide recommends pharmacologic treatment for postmenopausal women with a T-score between -1.0 and -2.5 at high 10-year risk of fracture with use of the United States-adapted fracture risk assessment (FRAX) tool provided by the World Health Organization (WHO) at www.shef.ac.uk/FRAX, where treatment is considered cost-effective if the 10-year risk is 3% or more for hip fracture or 20% or more for “major” osteoporosis-related fracture (humerus, forearm, hip, or clinical vertebral fracture).

Method of Guideline Validation

Peer Review

Description of Method of Guideline Validation

Not stated

Recommendations

Major Recommendations

The levels of evidence (1 to 4) and the recommendation grades (A to D) are defined at the end of the “Major Recommendations” field.

Executive Summary of Recommendations

The following recommendations (labeled “R”) are evidence based (Grades A, B, and C) or are based on expert opinion because of a lack of conclusive clinical evidence (Grade D). The best evidence level (BEL), which corresponds to the best conclusive evidence found, accompanies the recommendation grade in this Executive Summary.

What Measures Can Be Taken to Prevent Bone Loss?

R1. Maintain adequate calcium intake; use calcium supplements, if needed, to meet minimal required intake (Grade A; BEL 1).
R2. Maintain adequate vitamin D intake; supplement vitamin D, if needed, to maintain serum levels of 25-hydroxyvitamin D [25(OH)D] between 30 and 60 ng/mL (Grade A; BEL 1).
R3. Limit alcohol intake to no more than 2 servings per day (Grade B; BEL 2).
R4. Limit caffeine intake (Grade C; BEL 3).
R5. Avoid or stop smoking (Grade B; BEL 2).
R6. Maintain an active lifestyle, including weight-bearing exercises for at least 30 minutes daily (Grade B; BEL 2).

What Nonpharmacologic Measures Can Be Recommended for Treatment of Osteoporosis?

All the foregoing measures plus the following:

R7. Maintain adequate protein intake (Grade B; BEL 3).
R8. Use proper body mechanics (Grade B; BEL 1).
R9. Consider the use of hip protectors in individuals with a high risk of falling (Grade B; BEL 1).
R10. Take measures to reduce the risk of falling (Grade B; BEL 2).
R11. Consider referral for physical therapy and occupational therapy (Grade B; BEL 1).

Who Needs to Be Screened for Osteoporosis?

R12. Women 65 years old or older (Grade B; BEL 2).
R13. Younger postmenopausal women at increased risk of fracture, based on a list of risk factors (see section 4.5 in the original guideline document) (Grade C; BEL 2).

How Is Osteoporosis Diagnosed?

R14. Use a central dual-energy x-ray absorptiometry (DXA) measurement (Grade B; BEL 3).
R15. In the absence of fracture, osteoporosis is defined as a T-score of -2.5 or below in the spine (anteroposterior), femoral neck, or total hip (Grade B; BEL 2).
R16. Osteoporosis is defined as the presence of a fracture of the hip or spine (see section 4.4.2 in the original guideline document) (in the absence of other bone conditions) (Grade B; BEL 3).

How Is Osteoporosis Evaluated?

R17. Evaluate for secondary osteoporosis (Grade B; BEL 2).
R18. Evaluate for prevalent vertebral fractures (see section 4.7.1 in the original guideline document) (Grade B; BEL 2).

Who Needs Pharmacologic Therapy?
R19. Those patients with a history of a fracture of the hip or spine (Grade A; BEL 1)
R20. Patients without a history of fractures but with a T-score of -2.5 or lower (Grade A; BEL 1)
R21. Patients with a T-score between -1.0 and -2.5 if Fracture Risk Assessment Tool (FRAX) (see section 4.5 in the original guideline document) major osteoporotic fracture probability is ≥20% or hip fracture probability is ≥3% (Grade A; BEL 2)

What Drugs Can Be Used to Treat Osteoporosis?
Use drugs with proven antifracture efficacy:
R22. Use alendronate, risedronate, zoledronic acid, and denosumab as the first line of therapy (Grade A; BEL 1).
R23. Use ibandronate as a second-line agent (Grade A; BEL 1).
R24. Use raloxifene as a second- or third-line agent (Grade A; BEL 1).
R25. Use calcitriol as the last line of therapy (Grade C; BEL 2).
R26. Use teriparatide for patients with very high fracture risk or patients in whom bisphosphonate therapy has failed (Grade A; BEL 1).
R27. Advise against the use of combination therapy (Grade B; BEL 2).

How Is Treatment Monitored?
R28. Obtain a baseline DXA, and repeat DXA every 1 to 2 years until findings are stable. Continue with follow-up DXA every 2 years or at a less frequent interval (Grade B; BEL 2).
R29. Monitor changes in spine or total hip bone mineral density (BMD) (Grade C; BEL 2).
R30. Follow-up of patients should be in the same facility, with the same machine, and, if possible, with the same technologist (Grade B; BEL 2).
R31. Bone turnover markers may be used at baseline to identify patients with high bone turnover and can be used to follow the response to therapy (Grade C; BEL 2).

What Is Successful Treatment of Osteoporosis?
R32. BMD is stable or increasing, and no fractures are present (Grade B; BEL 2).
R33. For patients taking antiestrogen agents, bone turnover markers at or below the median value for premenopausal women are achieved (see section 4.9 in the original guideline document) (Grade B; BEL 2).
R34. One fracture is not necessarily evidence of failure. Consider alternative therapy or reassessment for secondary causes of bone loss for patients who have recurrent fractures while receiving therapy (Grade B; BEL 2).

How Long Should Patients Be Treated?
R35. For treatment with bisphosphonates, if osteoporosis is mild, consider a "drug holiday" after 4 to 5 years of stability. If fracture risk is high, consider a drug holiday of 1 to 2 years after 10 years of treatment (Grade B; BEL 1).
R36. Follow BMD and bone turnover markers during a drug holiday period, and reinitiate therapy if bone density declines substantially, bone turnover markers increase, or a fracture occurs (Grade C; BEL 3).

When Should Patients Be Referred to Clinical Endocrinologists?
R37. When a patient with normal BMD sustains a fracture without major trauma (Grade C; BEL 4).
R38. When recurrent fractures or continued bone loss occurs in a patient receiving therapy without obvious treatable causes of bone loss (Grade C; BEL 4).
R39. When osteoporosis is unexpectedly severe or has unusual features (Grade C; BEL 4).
R40. When a patient has a condition that complicates management (for example, renal failure, hyperparathyroidism, or malabsorption) (Grade C; BEL 4).

**Definitions:**
2010 American Association of Clinical Endocrinologists Criteria for Rating of Published Evidence*

<table>
<thead>
<tr>
<th>Numerical Descriptor (evidence level)</th>
<th>Semantic Descriptor (reference methods)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Meta-analysis of randomized controlled trials</td>
</tr>
<tr>
<td>1</td>
<td>Randomized controlled trial</td>
</tr>
<tr>
<td>2</td>
<td>Meta-analysis of nonrandomized prospective or case-controlled trials</td>
</tr>
<tr>
<td>2</td>
<td>Nonrandomized controlled trial</td>
</tr>
<tr>
<td>2</td>
<td>Prospective cohort study</td>
</tr>
<tr>
<td>2</td>
<td>Retrospective case-control study</td>
</tr>
<tr>
<td>3</td>
<td>Cross-sectional study</td>
</tr>
<tr>
<td>3</td>
<td>Surveillance study (registries, surveys, epidemiologic study)</td>
</tr>
<tr>
<td>3</td>
<td>Consecutive case series</td>
</tr>
<tr>
<td>3</td>
<td>Single case reports</td>
</tr>
<tr>
<td>4</td>
<td>No evidence (theory, opinion, consensus, or review)</td>
</tr>
</tbody>
</table>

*1 = strong evidence; 2 = intermediate evidence; 3 = weak evidence; 4 = no evidence.
American Association of Clinical Endocrinologists Criteria for Grading of Recommendations

<table>
<thead>
<tr>
<th>Recommendation Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Homogeneous evidence from multiple well-designed randomized controlled trials with sufficient statistical power. Homogeneous evidence from multiple well-designed cohort controlled trials with sufficient statistical power ≥1 conclusive level 1 publications demonstrating benefit &gt;&gt; risk.</td>
</tr>
<tr>
<td>B</td>
<td>Evidence from at least 1 large well-designed clinical trial, cohort or case-controlled analytic study, or meta-analysis, No conclusive level 1 publication; ≥1 conclusive level 2 publications demonstrating benefit &gt;&gt; risk.</td>
</tr>
<tr>
<td>C</td>
<td>Evidence based on clinical experience, descriptive studies, or expert consensus opinion. No conclusive level 1 or 2 publications; ≥1 conclusive level 3 publications demonstrating benefit &gt;&gt; risk.</td>
</tr>
<tr>
<td>D</td>
<td>Not rated. No conclusive level 1, 2, or 3 publication demonstrating benefit &gt;&gt; risk. Conclusive level 1, 2, or 3 publication demonstrating risk &gt;&gt; benefit.</td>
</tr>
</tbody>
</table>


Clinical Algorithm(s)
None provided

Evidence Supporting the Recommendations

Type of Evidence Supporting the Recommendations
The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).

Benefits/Harms of Implementing the Guideline Recommendations

Potential Benefits
Appropriate screening, evaluation, management (including pharmacologic and nonpharmacologic treatment), and monitoring of women with osteoporosis at or high risk of osteoporosis.

Potential Harms
- Side effects of pharmacotherapy
- Patients with severe osteoporosis should avoid engaging in motions such as forward flexion exercises, using heavy weights, or even performing side-bending exercises because pushing, pulling, lifting, and bending exert compressive forces on the spine that may lead to fracture. An initial visit with a physical therapist may help clarify what exercises are safe and unsafe to do.

Contraindications

Contraindications
Bisphosphonates
Contraindications to bisphosphonate therapy include hypersensitivity or hypocalcemia. Bisphosphonates should be used with caution, if at all, in patients with reduced kidney function (glomerular filtration rate below 30 mL/min for risedronate and ibandronate or below 35 mL/min for alendronate and zoledronate).

Raloxifene
Raloxifene is contraindicated in women of childbearing potential, those who have had venous thromboembolic disease, or those who are known to be hypersensitive to any component of raloxifene tablets.

Teriparatide
Because teriparatide caused an increased incidence of osteosarcomas in rats, it is contraindicated in patients at increased risk of osteosarcoma (those with Paget disease of bone, open epiphyses, a history of irradiation involving the skeleton, or an unexplained elevation of alkaline phosphatase level of skeletal origin). Teriparatide should also not be administered to
an unexplained elevation of alkaline phosphatase level of skeletal origin. Teriparatide should also not be administered to patients with primary or any form of secondary untreated or unresolved hyperparathyroidism.

**Calcitonin**

The main contraindication to use of calcitonin is hypersensitivity. For patients with suspected sensitivity to the drug, skin testing is recommended before treatment.

**Estrogen and Menopausal Hormone Therapy**

The following are contraindications to estrogen or combination estrogen-progestin therapy:

- Known or suspected pregnancy
- Known or suspected cancer of the breast
- Known or suspected estrogen-dependent neoplasm
- Undiagnosed abnormal genital bleeding
- Active thrombophlebitis or thromboembolic disorders or a history of thromboembolic disease
- Sensitivity to the hormones

**Qualifying Statements**

These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable. The American Association of Clinical Endocrinologists (AACE) encourages medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances.

**Implementation of the Guideline**

**Description of Implementation Strategy**

An implementation strategy was not provided.

**Institute of Medicine (IOM) National Healthcare Quality Report Categories**

**IOM Care Need**

- Living with Illness
- Staying Healthy

**IOM Domain**

- Effectiveness
- Patient-centeredness

**Identifying Information and Availability**

**Bibliographic Source(s)**


**Adaptation**

Not applicable: The guideline was not adapted from another source.

**Date Released**

1996 Mar-Apr (revised 2010 Nov-Dec)

**Guideline Developer(s)**

American Association of Clinical Endocrinologists - Medical Specialty Society

**Source(s) of Funding**

Financial support for this guideline was provided by Wyeth-Ayerst Pharmaceuticals, Merck & Co., Inc., Proctor & Gamble Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., and Eli Lilly and Company.

**Guideline Committee**

Osteoporosis Task Force
Composition of Group That Authored the Guideline

Osteoporosis Task Force Members: Nelson B. Watts, MD, FACP, MACE (Chair); John P. Bilizikian, MD, MACE; Pauline M. Camacho, MD, FACE; Susan L. Greenspan, MD, FACP, FACE; Steven T. Harris, MD, FACE; Stephen F. Hodgson, MD, FACP, MACE; Michael Kleerekoper, MD, MACE; Marjorie M. Luckey, MD, FACE; Michael R. McClung, MD, FACP, FACE; Rachel Pessah Pollack, MD; Steven M. Petak, MD, JD, FACE, FCLM

Reviewers: Donald A. Bergman, MD, FACP, FACE; Neil Binkley, MD; Paul D. Miller, MD, FACP

Financial Disclosures/Conflicts of Interest

Chair


Task Force Members

Dr. John P. Bilizikian reports that he has received speaker honoraria from Amgen Inc., Eli Lilly and Company, and Novartis AG and consultant honoraria from Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., and Warner Chilcott.

Dr. Pauline M. Camacho reports that she has received research grant support for her role as principal investigator from Eli Lilly and Company and Procter & Gamble.

Dr. Susan L. Greenspan reports that she has received consult honoraria from Amgen Inc. and Merck & Co., Inc. and research grant support for her role as principal investigator from the Alliance for Better Bone Health (Procter & Gamble/sanofi-aventis U.S. LLC), Eli Lilly and Company, and Warner Chilcott.

Dr. Steven T. Harris reports that he has received speaker honoraria from Amgen Inc., Genentech, Inc., Gilead, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Novartis AG, Procter & Gamble, sanofi-aventis U.S. LLC, and Warner Chilcott and consultant honoraria from Amgen Inc., Gilead, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Merck & Co., Inc., and Novartis AG.

Dr. Stephen F. Hodgson reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Michael Kleerekoper reports that he has received speaker honoraria from Amgen Inc. and Eli Lilly and Company and speaker and consultant honoraria from F. Hoffmann-La Roche Ltd Diagnostics.

Dr. Marjorie M. Luckey reports that she has received speaker honoraria and consultant fees from Amgen Inc. and Novartis AG.

Dr. Michael R. McClung reports that he has received research grant support, consulting fees, and/or speakers' bureau honoraria from Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, and Warner Chilcott.

Dr. Rachel Pessah Pollack reports that she does not have any relevant financial relationships with any commercial interests.

Dr. Steven M. Petak reports that he has received speaker honoraria from Amgen Inc. and the International Society for Clinical Densitometry.

Guideline Status

This is the current release of the guideline.


Guideline Availability


Print copies: Available from the American Association of Clinical Endocrinologists (AACE), 245 Riverside Avenue, Suite 200, Jacksonville, FL 32202.

Availability of Companion Documents

The following is available:


Print copies: Available from the American Association of Clinical Endocrinologists (AACE), 245 Riverside Avenue, Suite 200, Jacksonville, FL 32202.

Patient Resources
None available

NGC Status

This summary was completed by ECRI on August 28, 2001, and updated on February 13, 2004. The updated information was verified by the guideline developer on March 29, 2004. This summary was updated by ECRI on May 20, 2005, following the U.S. Food and Drug Administration advisory on Aredia (pamidronate disodium) and Zometa (zoledronic acid). This summary was updated by ECRI on June 16, 2005, following the latest U.S. Food and Drug Administration advisory on COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). This NGC summary was updated by ECRI Institute on February 14, 2012. The updated information was verified by the guideline developer on March 6, 2012.

Copyright Statement

All rights reserved. No part of these materials may be reproduced or retransmitted in any manner without the prior written permission of the American Association of Clinical Endocrinologists.

Disclaimer

NGC Disclaimer

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion-criteria.aspx.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.